ICCM IceCure Medical Ltd.

NASDAQ
$1.00

IceCure Medical Ltd. Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Conference Operator
Operator
Good morning and thank you for standing by. All participants are currently in listen-only mode. Following management's prepared remarks, we will open the call for question and answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference call over to Sarah Velling. Please go ahead.
Sarah Velling
Investor Relations
Before we begin, I will take a moment to read the forward-looking statements disclaimer. This call and the question and answer session that follows contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions are intended to identify forward-looking statements. These statements include, among other things, the company's expectations regarding continued revenues, commercial expansion, physician adoption and utilization of proteins, expansion of its U.S. commercial organization and international presence, investing in the company's commercial, clinical, and organizational capabilities, the progress and potential impact of the CHOICE post-marketing study, future clinical evidence generation, Intellectual Property Protection, and the Company's Long-Term Market Opportunity. These forward-looking statements are subject to risks and uncertainties, many of which are beyond the company's control. These risks are described in greater detail in the Risk Factor section of the company's annual report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and in other documents filed with or furnished to the SEC. The company undertakes no obligation to update or revise any forward-looking statements except as required by law. This conference call contains time-sensitive information and speaks only as of today's live broadcast, November 18, 2026. I will now turn the call over to IceCure Medical's CEO, Eyal Shamir. Eyal, please go ahead.
Eyal Shamir
Chief Executive Officer
Thank you, operator, and thank you everyone for joining us today. The first nine months of 2026 demonstrated continued commercial momentum for process, particularly in the United States, our primary commercial market. Total revenue increased 26% year over year, while U.S. sales increased 83%, reflecting the continued expansion of our commercial activities and growing adoption of process. During the third quarter, we also continue to expand our U.S. commercial presence, advance the choice post-marketing study, and strengthen the clinical evidence supporting prior ablation. We believe that development demonstrates the progress we are making in translating the clinical and regulatory foundation we have built over the past several years into commercial growth and broader physician adoption. Let me start with our financial and commercial performance in the United States. By the end of the third quarter of 2026, we nearly doubled our U.S. commercial footprint, growing from 11 states to the end of the second quarter of 2025 to 21 states. We added dedicated sales and marketing professionals in key regions, including New York, Southern California, the Midwest, and Florida, as well as additional clinical support personnel. This expansion commercial infrastructure enable us to engage with small physician and medical institutions, provide clinical support and training, and support the adoption of your utilization of process. We believe the combination of broadened geographic coverage, the expanded commercial team, and increased physician engagement provide a stronger foundation for our continued U.S. commercial growth. Another important area of progress is our choice post-marketing study. which we designed to generate additional clinical evidence while expanding physician experience with process. Since initiating the study, we have newly established three clinical sites including West Cancer Center in Germantown, Tennessee, Advances Health Glendon in Glendon, California, and Legacy Health in Portland, Oregon, and have begun enrolling and treating patients at participating US centers. We progress from activating our first clinical site to enrolling and treating the first patients at West Clinic Center in Tennessee and have since announced initial patients enrolled at two participating U.S. clinical sites. We are also engaging with additional leading medical centers regarding potential participation in the study. We view CHOICE as closely connected to our broader commercial strategy and additional leading institutions and physicians gain clinical experience in this process The study can generate real-world evidence, support physician confidence, and contribute to a broader adoption over time. Beyond our commercial and clinical progress in the United States, we continue to expand the regulatory and commercial footprint of ProSense internationally. Recent development includes regulatory approval in China and inclusive distribution agreement in the Netherlands. Further expanding the market in which ProSense can be commercialized. We also seeing continued interest in physician and medical institution in Europe South America and other international markets as we work to build a regulatory and commercial relationship union to support broader adoptions of process. At the same time, we continue the scientific foundation supporting cryoablation. During the third quarter, we highlighted two additional peer-reviewed scientific publications addressing the role of cryoablation in breast cancer treating De-escalation including research relating to early stage breast cancer and axillary lymph node metastasis. We believe the continued generation of independent scientific evidence can further support physician awareness and confidence in cryoablation and contribute to broader adoption over time. In parallel, we continue to strengthen our intellectual property portfolio as processes expand into additional markets and gain broader commercial exposure. We consider our IP an important strategic asset and remain focused on protecting the technology's underlying process as we pursue browser commercial adoption globally. Taking together this development reflects the progress we are making across our commercial, clinical, and international activities. Our focus remains executing, expanding our commercial presence, increasing physician adoption and utilization of process, Advancing our clinical program and building the evidence needed to support broader adoption. While we are still in the early stage of realizing the commercial opportunity for protons, we believe the progress we are seeing, particularly in the United States, provides a stronger foundation for continued growth. With that, I will turn the call over to our Chief Financial Officer, Meir Peleg, who will review our financial results in greater detail.
Meir Peleg
Chief Financial Officer
Thank you, Eyal, and good morning everyone. I will briefly review our financial results for the nine-month end of September 30, 2026. Total revenues for the first nine months of 2026 increased approximately 26% to $2.6 million, compared to $2.1 million in the corresponding period of 2025. Gross Profit increased approximately 22% to $762,000 compared to $626,000 in the prior year period. As Eyal mentioned, we are particularly pleased with the growth in the United States where sales increased 83% year-over-year during the first nine months of the year. This performance reflects the continued expansion of our commercial activities and the growing market presence of process. Regarding operating expenses, existing development expenses were approximately $6.5 million compared to $5.1 million in the corresponding period last year. The increase primarily reflects higher expenses related to the Choice Post-Marketing Study and other clinical and development activities. Telvin marketing expenses increased approximately 20% to $3.6 million compared to $3 million in the prior year period, primarily reflecting the continued expansion of our U.S. commercial activities while U.S. sales grew 83% over the same period. General business sales expenses were approximately $3.5 million compared to $3.3 million in the corresponding period of 2025. Operating loss for the first nine months of 2026 Net loss was approximately 12.9 million compared to 10.8 million during the first 9 months of 2025. As of September 30, 2026, Cash and cash equivalents totaled approximately 8.2 million compared to approximately 8.9 million year-end 2025. We continue to carefully manage our financial resources while investing in the commercial, clinical, and organizational capabilities that we believe are essential to supporting our long-term growth strategy. Our investment in expanding the U.S. Commercial Organization and advancing the Choice Study reflects our commitment to building the infrastructure and clinical evidence needed to support broader adoption of process. With that, I will turn the call back to the operator to open the line for questions.
Conference Operator
Operator
Thank you. Ladies and gentlemen, at this time we will begin the question and answer session. If you have a question, please press star 1. If you wish to cancel your request, please press star 2. If you are using speaker equipment, kindly leave the answer before pressing the numbers. Your questions will be pulled in the order they are received. Please stand by while we pull for your questions.
Conference Operator
Operator
The first question is from Scott Henry of AGP. Please go ahead.
Scott Henry
Analyst, AGP
Thank you and good morning or afternoon depending on location. Starting on the revenue side, last year we saw a significant sequential boost in Q4 of the year. Do you think we'll see that this year, or is that kind of a one-time event? Thank you.
Eyal Shamir
Chief Executive Officer
Scott, may I please answer that, and if needed, Shad will add to it?
Meir Peleg
Chief Financial Officer
Thank you for the question.
Shad
Vice President of Sales, North America
I can speak specifically to the United States. We feel like we're starting to get some real traction here in the U.S. and also getting some momentum with that. We would expect that our sales revenue would continue to increase quarter over quarter. Meir, do you want to talk about the rest of the world?
Meir Peleg
Chief Financial Officer
Yeah, I think we showed and it's also been seen in the square that we have some kind of seasonality. You know, revenue, while Q3 is mostly weaker than the others, together with Q1, Q4 is Tlalit Bussi Tel-Tzure Tlalit Bussi Tel-Tzure Tlalit Bussi Tel-Tzure
Scott Henry
Analyst, AGP
How the revenue ramp should continue. It sounds like things are picking up and we should see accelerating revenue growth in 2027. But I just wanted to get your thoughts on it.
Meir Peleg
Chief Financial Officer
Thank you. Again, we're not giving guidance and thank you for the question. It's a good one. We do see acceleration in sales and the projection for next year for revenue is a healthy double-digit growth.
Scott Henry
Analyst, AGP
Okay, great. And then if I could just get one final question. On the choice study, are you getting, you know, what kind of early feedback are you getting? Are the physicians finding it easy to move up the learning curve? Just any kind of feedback you're getting from the early days. Thank you.
Eyal Shamir
Chief Executive Officer
Hi Scott, this is Eyal. I will answer that and if needed, Shad and our VP Cells for North America and Shai, our COO, will be able to add. So, as we announced the first two sites, one of them is running by Dr. Richard Fein, together with some of his colleagues, and West Clinic and Dr. Fein, they have very well experience, they participated to the I3 study and they did other cases. Same for Glendale, California, Dr. Dennis Horns, he is a long user, high volume user, so they are both experienced. One of the new sites that we announced by Dr. Natalie Johnson from Seattle, Oregon, past president, of the Society. She is a new user and she did some cases before at the PMS and she did the first case for the PMS so she found it for the patients and for the new users very easy to use, excellent minimally invasive solution so extremely satisfied with the cases that she did.
Scott Henry
Analyst, AGP
Great, thank you for taking the questions.
Conference Operator
Operator
The next question is from Kev Dolliver from Brookline Capital Markets. Please go ahead.
Keay Dolliver
Analyst, Brookline Capital Markets
Great, thank you. So, what's the installed base of consoles in the U.S. now?
Eyal Shamir
Chief Executive Officer
As you could see from the revenue growth and, as we announced, also new sites. Again, we are not giving guidelines. Last time that we discussed the active site was on June. We are still having some orders that we need to ship, to ship some orders before the end of the year, so I believe that In a few weeks or months or two, we will give some update information of that, but we definitely see a growth in cells and sites.
Keay Dolliver
Analyst, Brookline Capital Markets
Okay, good. And to clarify on the CHOICE study, are you currently at five sites?
Eyal Shamir
Chief Executive Officer
Yeah, Shad, could you take these questions?
Shad
Vice President of Sales, North America
Yes, we're currently at four sites as of today, but we're expecting to finalize some additional sites here in the very near future. So we've made some really good progress since the last call in regards to the recruiting process of sites, the contracting with the sites, and also kind of the commercial aspect as well. I think you should kind of expect to see kind of more of a steady cadence of new sites being enrolled into the study over the next couple of months.
Keay Dolliver
Analyst, Brookline Capital Markets
Okay, great. And the last question is, the commercial team, is it, you know, because a month or so ago it was around seven and you were thinking it would be nine at the end of the year, is that still your plan?
Eyal Shamir
Chief Executive Officer
So, Kemp, as you saw in the earnings release from this morning, recently, actually almost a week ago, we joined an excellent expert to support us in Florida, extremely important market. Two to three months ago, we had someone in California again. Again, excellent and very important market for future growth. We might add another one until the end of the year or very early next year. And next year we are planning, of course, to grow with the team in order to support the sales growth, as Meir mentioned, with important double-digit growth in the U.S. Great.
Keay Dolliver
Analyst, Brookline Capital Markets
Thank you. Thank you, Karen. Thank you.
Conference Operator
Operator
The next question is from Thomas McGovern from Maxim Group. Please go ahead.
Thomas McGovern
Analyst, Maxim Group
Hey, guys. Thanks for taking my question. The first one's just on the choice study. Following the second quarter update, we were anticipating the first patient to be enrolled in September, and we saw the update that they were treated back in October. Just curious, where's that pipeline now, and what's your outlook compared to those deadlines that we've discussed in the past? We were expecting 80 patients by the end of March 26th. Deadlines you believe you're on track to hit?
Eyal Shamir
Chief Executive Officer
You know, I'm not sure that we will be able to do the 400 within the three years because, you know, some of the contracts, you know, agreement, some of the sites is taking them longer time. Early this year, you know, we had some difficulties, you know, to travel, but we are joining Eyal Shamir, Tlalit Bussi Tel-Tzure will be on board, and I know that some of them are having even patients that really fit to the trial and waiting to be treated. But at the moment, it's a bit too early to say that it will be able to meet the 400 exactly three years, or maybe some short time after that, or whatever.
Thomas McGovern
Analyst, Maxim Group
Okay, and you guys have some flexibility to go to the FDA and kind of articulate that case and get some extension time there?
Eyal Shamir
Chief Executive Officer
We have a continuous communication with the FDA. We are giving them also updates. Of course, we will discuss it with them in a mutual way. We would like to see the patients, and they like to see the patients, so I'm sure that we will come to a mutual agreement on that.
Thomas McGovern
Analyst, Maxim Group
Okay, great to hear. On the international side of the business, you guys gave updates on the approvals for both regulatory and IP approvals in China and the Netherlands distributor. I'm just curious, you know, how do you guys plan to go to market in China? Are you guys expecting to do a partnership, you know, have a distributor relationship? And when can we start to see that revenue come in? And the follow-up questions would be on Japan and Canada. Just curious if we can get an update on timelines for approval on that front.
Eyal Shamir
Chief Executive Officer
Yeah. Okay, so I will start with... With China, we are now in discussions with some potential partners, mainly more as a mode of distribution. In China, of course, you need to work with them, you know, in a closed partnership, but it will be more like a distribution. So as soon as Google has something in place, we will do a proper announcement as needed. So we are working on that. Health Canada, we are waiting on the breast cancer Canada Health approval and it could be in the next few weeks. Maybe it will take, you know, two to four months. We expect, we answer them all the questions that they have and we're expecting to get approval in the next few months. And Japan, We expect that Torumo will make the submission to the Japanese FDA to the PMDA during the first semester of 27.
Thomas McGovern
Analyst, Maxim Group
Understood. I appreciate you answering all my questions.
Eyal Shamir
Chief Executive Officer
Thank you.
Conference Operator
Operator
If there are any additional questions, please press star 1. There are no further questions at this time. I will turn the call over to Eyal Shamir for concluding state remarks, please.
Eyal Shamir
Chief Executive Officer
Thank you everyone for questions and for joining us today. As we look ahead, our priorities are clear. Accelerating U.S. commercial growth, expand physician adoptions, and Utilization of Process Advanced Choice Study and continue building the clinical evidence supporting prior updation. With U.S. sales up to 83 year-over-year during the first nine months of 2026, an extended commercial footprint and continuous clinical progress, we believe we are building a solid foundation for the next phase of process commercialization. We remain focused on execution and on translating this progress into broader adoptions and long-term value for our shareholders. Thank you again for your continuous interest and support. We look forward to updating you on our progress.
Conference Operator
Operator
This concludes the iSecure Medical third quarter and nine months 2026 financial results conference call. Thank you for your participation. You may go ahead and disconnect.